Stryker Corporation 10-Q Summary: Q1 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002. Stryker Corporation operates in two primary reportable segments: Orthopaedic Implants (reconstructive, trauma, and spinal implants) and MedSurg Equipment (powered surgical instruments, endoscopic systems, and hospital beds). The company also reports "Other" activities, including Physical Therapy Services and corporate administration.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $702.9 million | $634.2 million |
| Gross Profit | $448.0 million (63.7% margin) | $401.9 million (63.4% margin) |
| Net Earnings | $81.1 million | $64.1 million |
| Diluted EPS | $0.40 | $0.32 |
| Operating Cash Flow | $62.7 million | $74.6 million |
| Cash and Equivalents | $60.9 million | $50.1 million (Dec 31, 2001) |
| Total Debt | $705.4 million | $722.6 million (Dec 31, 2001) |
| Working Capital | $535.7 million | $459.7 million (Dec 31, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% year-over-year, driven by a 10% increase in unit volume, 2% price increases, and 1% from acquisitions. This was partially offset by a 2% negative impact from foreign currency exchange rates.
- Profitability: Net earnings rose 27% to $81.1 million. Gross margin improved slightly to 63.7% due to better absorption of manufacturing costs.
- Accounting Change (FAS 142): The adoption of FASB Statement No. 142 eliminated goodwill amortization. This reduced intangibles amortization expense by $3.9 million and increased net earnings by $2.6 million ($0.01 per diluted share) compared to the prior year.
- Expense Classification: Stryker Biotech reclassified costs from R&D to Cost of Sales and SG&A following the commercial launch of the OP-1 Implant, reducing reported R&D expenses by 5%.
- Interest Expense: Declined significantly to $10.6 million from $19.5 million due to lower debt balances and interest rates.
Outlook, Risks, and Management Commentary
- Segment Performance: Orthopaedic Implants sales grew 10% (13% excluding currency), while MedSurg Equipment sales grew 12% (14% excluding currency). Physical Therapy Services grew 13%.
- Liquidity: The company generated $62.7 million in operating cash flow. Total borrowings declined by $17.2 million during the quarter. The company maintains $330.3 million in additional borrowing capacity.
- Inventory: Days sales in inventory increased to 147 days from 138 days, attributed to increased production to meet demand.
- Goodwill Impairment: The initial impairment test under FAS 142 was completed; no goodwill write-down was deemed necessary.
- Risks: Key risks include regulatory actions affecting pricing, changes in third-party reimbursement levels, product liability claims, and foreign exchange volatility. Foreign currency translation adjustments reduced equity by $19.6 million in the quarter.
Investor Verification Checklist
- Verify the sustainability of the 11% sales growth given the 2% headwind from foreign currency rates.
- Monitor the trend in Days Sales in Inventory (147 days) to ensure it does not signal overstocking or demand softness.
- Review the impact of the FAS 142 accounting change on future earnings comparisons, as goodwill amortization is no longer a recurring expense.
- Assess the company's ability to maintain gross margins as manufacturing capacity utilization fluctuates.
- Confirm the status of the $250 million 364-day revolving credit agreement expiring in December 2002.